Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001641172-25-005014
Filing Date
2025-04-16
Accepted
2025-04-16 14:51:33
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6261
  Complete submission text file 0001641172-25-005014.txt   8370
Mailing Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852
Business Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 732 545 1590
Ayala Pharmaceuticals, Inc. (Filed by) CIK: 0001100397 (see all company filings)

EIN.: 841521955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Subject) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94604 | Film No.: 25842248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)